Sung Ji Nam
Stock Analyst at Scotiabank
(3.45)
# 981
Out of 5,050 analysts
83
Total ratings
50%
Success rate
4.95%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $96.72 | -37.97% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $57.41 | +30.64% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $209.94 | +30.99% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $572.41 | +3.07% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $121.90 | +2.54% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $33.04 | +21.07% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $7.73 | +417.46% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $6.30 | -4.76% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.63 | +145.40% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.76 | +13.64% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $66.18 | +10.31% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $14.79 | -18.86% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $371.69 | +21.07% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $30.27 | +104.82% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $41.70 | +5.52% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $15.62 | +124.07% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.71 | +27.39% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.36 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $96.72
Upside: -37.97%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $57.41
Upside: +30.64%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $209.94
Upside: +30.99%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $572.41
Upside: +3.07%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $121.90
Upside: +2.54%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $33.04
Upside: +21.07%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $7.73
Upside: +417.46%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $6.30
Upside: -4.76%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.63
Upside: +145.40%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.76
Upside: +13.64%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $66.18
Upside: +10.31%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $14.79
Upside: -18.86%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $371.69
Upside: +21.07%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $30.27
Upside: +104.82%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $41.70
Upside: +5.52%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $15.62
Upside: +124.07%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.71
Upside: +27.39%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $26.36
Upside: -